TY - JOUR
T1 - Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40
AU - Herbort, Carl P.
AU - de Smet, Marc D.
AU - Roberge, François G.
AU - Nussenblatt, Robert B.
AU - Fitzgerald, David
AU - Lorberboum-Galski, Haya
AU - Pastan, Ira
PY - 1991/9
Y1 - 1991/9
N2 - IL-2-PE40 is a recombinant chimeric protein composed of IL-2, fused to a modified pseudomonas exotoxin. This molecule is extremely toxic to activated T cells expressing high-affinity IL-2R. We used this new molecule for selective immunosuppression to treat corneal allograft rejection in the rat, using Fisher and Lewis rats, a strain combination differing only in medial and minor histocompatibility antigens. The effect of IL- 2-PE40 on the immunologic response was studied using both a heterotopic corneal graft model and orthotopic grafts. At the dose of 0.31 pg/g given intraperitoneally every 12 hr, IL-2-PE40 produced a significant reduction of both total lymph node cells and cytotoxic-T-cell (CTL) activity in draining lymph nodes (DLN) of het- erotopically grafted animals. IL-2-PE40 treatment also significantly reduced the clinical rejection score and cumulative rejection rate (CRR) in orthotopic grafts and appears to be a very effective immunosuppressive agent.
AB - IL-2-PE40 is a recombinant chimeric protein composed of IL-2, fused to a modified pseudomonas exotoxin. This molecule is extremely toxic to activated T cells expressing high-affinity IL-2R. We used this new molecule for selective immunosuppression to treat corneal allograft rejection in the rat, using Fisher and Lewis rats, a strain combination differing only in medial and minor histocompatibility antigens. The effect of IL- 2-PE40 on the immunologic response was studied using both a heterotopic corneal graft model and orthotopic grafts. At the dose of 0.31 pg/g given intraperitoneally every 12 hr, IL-2-PE40 produced a significant reduction of both total lymph node cells and cytotoxic-T-cell (CTL) activity in draining lymph nodes (DLN) of het- erotopically grafted animals. IL-2-PE40 treatment also significantly reduced the clinical rejection score and cumulative rejection rate (CRR) in orthotopic grafts and appears to be a very effective immunosuppressive agent.
UR - http://www.scopus.com/inward/record.url?scp=0026048242&partnerID=8YFLogxK
U2 - 10.1097/00007890-199109000-00015
DO - 10.1097/00007890-199109000-00015
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 1897019
AN - SCOPUS:0026048242
SN - 0041-1337
VL - 52
SP - 470
EP - 474
JO - Transplantation
JF - Transplantation
IS - 3
ER -